Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SRZN · against 386 other Healthcare companies of similar size
Ranked #239 of 387 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score149 peers with a valuation score of 0–9, including SRZN · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SRZN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 372 reported | -133.0% | -0.3% | 0% | 30% | |
| EBITDA yieldHigher is better · 391 reported | -17.2% | 2.1% | 17% | 50% | |
| Free cash flow yieldHigher is better · 187 reported | -9.9% | -9.2% | 47% | 20% | |
| Book yieldHigher is better · 381 reported | -61.8% | 50.1% | 2% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 239 | 223M USD | 8 | 34 | |
| 239 | 673M USD | 8 | 35 | |
| 239 | 588M USD | 8 | 24 | |
| 239 | 303M USD | 8 | 27 | |
| 239 | 354M USD | 8 | 13 | |
| 239 | 467M USD | 8 | 44 | |
| 239 | 549M USD | 8 | 30 | |
| 239 | 371M USD | 8 | ||
| 239 | 394M USD | 8 | 37 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score